Insider buying last 90 days
No open-market insider purchases were filed for IBRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IBRX insider filing, plotted on the chart in Gekko.Open IBRX in Gekko
NASDAQ: IBRX
ImmunityBio (IBRX) Stock Analysis & Forecast
Sep 28 close
$8.52+0.08 (+0.9%)
Gekko Brief
AI summaryImmunityBio shares climbed after founder Dr. Patrick Soon-Shiong met with Turkish President Recep Tayyip Erdogan, a sign of progress on expansion into Turkey's cancer care market, with shares reported climbing nearly 10% on the news. Separately, speculation emerged around a possible tokenized version of IBRX shares after the founder teased a push into blockchain-based stock trading at Nant. The company also took part in the World Bladder Cancer Patient Forum 2026 in Hong Kong, where ImmunityBio's Anjali Malhotra discussed patient-centric clinical trial design in bladder cancer.
IBRX closed at $8.52, up 0.9%, sitting above both its 50-day average of $7.85 and its 200-day average of $7.06, with the 50-day above the 200-day. The GekkoIndex reads 55.5, placing the stock in the Neutral zone, up 3.8 over five days. Price sits 13.1% below Gekko Fair Value of $9.81.
The next earnings report is set for 3 November 2026, 35 days out and outside a typical 20-trading-day hold; the prior report on 4 August 2026 showed an EPS of -0.22 against a -0.08 estimate, with a 1.4% reaction, and the average absolute reaction has run 10.4%. Seasonality from this point in the calendar has averaged 1.2% over the next 20 trading days across 5 years, rising in 2 of them. No insider, Congress or unusual options activity appears in the current windows, and one trailblazer holder is noted among current positions.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
ImmunityBio price vs fair value
Close $8.52200-day averageGekko Fair Value $9.81
ImmunityBio quick facts
- Market cap
- $8.92B
- P/E ratio
- —
- Forward P/E
- 123.5
- EPS, TTM
- −$0.95
- Revenue, TTM
- $165.8M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.14
- Volume
- 10.37M avg 10.26M
- 1-year return
- +246.3%
- Typical daily move
- ±6.9%
- Typical 20-day move
- ±14.3%
- 50-day average
- $7.85
- 200-day average
- $7.06
- Next earnings
- Nov 3
- Shares outstanding
- 1.06B
ImmunityBio swing-trade checklist
ImmunityBio scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $8.52 is above the 50-day ($7.85) and 200-day ($7.06) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.5, Neutral
Reading 55.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
13.1% below
Price is 13.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.2% on average
From this point in the calendar, the next 20 trading days averaged +1.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ImmunityBio stock chart and price history
ImmunityBio closed at $8.52 on Sep 28, 2026, +246.3% over the past year, inside a 52-week range of $1.95 to $12.43.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.4%
- 3 months
- −2.9%
- 6 months
- +15.4%
- 1 year
- +246.3%
The full IBRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IBRX in Gekko
Follow ImmunityBio through every session
Put IBRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IBRX in GekkoFree for 7 days. No credit card required.
About ImmunityBio
ImmunityBio works on medicines still in clinical testing, aimed at cancer and infectious disease. It builds its work around a range of immune-based approaches, including antibody-cytokine fusion proteins, engineered immunomodulators, vaccine technologies, natural killer cell therapies, and methods that engage the body's T-cell response. Several of its treatment candidates have reached Phase II or III trials, targeting tumors such as bladder, pancreatic, and lung cancer, along with pathogens like SARS-CoV-2 and HIV.
The company pursues its research partly through outside collaboration, working with organizations such as the National Cancer Institute and the National Institute of Deafness and Communication Disorders, as well as Amyris. It also holds licensing agreements with a number of firms, among them CytRx, EnGeneIC, GlobeImmune, the Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology, Sorrento Therapeutics, and Viracta Therapeutics, reflecting a network of shared research and technology arrangements rather than a single in-house pipeline.
ImmunityBio was founded in 2014 and is based in San Diego, California. Its shares are listed on the NASDAQ under the ticker IBRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- immunitybio.com
ImmunityBio GekkoIndex: the smart money zone
ImmunityBio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.5, in the Neutral zone, up 3.8 points over five sessions.
55.5Neutral
Up 3.8 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +2.7% | +10.2% | ||
| Accumulation | 254 | +2.9% | +14.5% | ||
| Neutral (current zone) | 331 | +0.8% | +0.8% | ||
| Distribution | 36 | +3.5% | +5.3% | ||
| Selling | 7 | Too few readings yet | |||
Average IBRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the IBRX price, zone by zone.Track IBRX in Gekko
Is ImmunityBio stock overvalued? Gekko Fair Value
ImmunityBio trades 13.1% below Gekko Fair Value of $9.81, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ImmunityBio shares are worth, recalculated every trading day.
$9.81
Gekko Fair Value, Sep 29, 2026
13.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open IBRX in Gekko
ImmunityBio insider and Congress trading
No open-market insider purchases were filed for ImmunityBio, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IBRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IBRX, plotted on the chart in Gekko.Open IBRX in Gekko
Buybacks
ImmunityBio has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2023
- $1.46M
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds IBRX.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
ImmunityBio earnings: next date and track record
ImmunityBio reports on Nov 3, 2026 (35 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
35 days away
- EPS estimate
- −$0.08
- Revenue estimate
- $59.23M
5 of 8reports beat the EPS estimate
±10.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.22 est −$0.08 | $51.24M est $49.70M | +1.4% |
| May 7, 2026 | −$0.08 est −$0.07 | $44.21M est $43.07M | +1.6% |
| Feb 23, 2026 | −$0.06 est −$0.11 | $38.29M est $38.36M | +32.8% |
| Nov 4, 2025 | −$0.07 est −$0.10 | $32.06M est $37.78M | −4.9% |
| Aug 5, 2025 | −$0.10 est −$0.10 | $26.43M est $31.88M | −1.2% |
| May 12, 2025 | −$0.15 est −$0.16 | $16.52M est $16.60M | +21.3% |
| Mar 3, 2025 | −$0.08 est −$0.13 | $7.55M est $9.63M | −8.2% |
| Nov 12, 2024 | −$0.12 est −$0.18 | $6.11M est $9.07M | −11.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ImmunityBio stock forecast and analyst price targets
Analysts’ average 12-month price target for ImmunityBio is $12.75, +49.6% from the last close, from 2 firms rating the stock in the last 90 days.
$12.75consensus 12-month target, +49.6% from the last close
Now $8.52Avg $12.75
Low $12High $15
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 8 | Piper Sandler | $12 | +40.8% |
| Aug 4 | H.C. Wainwright | $15 | +76.1% |
+0.8%average 20-day move after past Neutral readings
+1.2%average move over the next 20 trading days in the last 5 years
±6.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ImmunityBio seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, ImmunityBio averaged +1.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.3% | 2 of 5 |
| Next 10 trading days | −3.4% | 1 of 5 |
| Next 15 trading days | −1.5% | 2 of 5 |
| Next 20 trading days | +1.2% | 2 of 5 |
| Next 30 trading days | +34.0% | 3 of 5 |
For scale, IBRX’s typical 20-trading-day move in either direction is about 14.3%.
ImmunityBio market cap and key statistics
ImmunityBio’s market cap is $8.92B and revenue of $165.8M over the last twelve months.
Valuation
- Market cap
- $8.92B
- Forward P/E
- 123.5
- EPS, TTM
- −$0.95
- Gekko Fair Value
- $9.81
Trading
- Volume
- 10.37M
- Avg volume, 20 days
- 10.26M
- 52-week high
- $12.43
- 52-week low
- $1.95
- Shares outstanding
- 1.06B
Financials
- Revenue, TTM
- $165.8M
- Profit margin
- 0%
- Return on equity
- 0%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.14
- Typical daily move
- ±6.9%
- Typical 20-day move
- ±14.3%
ImmunityBio stock news this week
Coverage of ImmunityBio this week reads positive: 5 positive, 2 neutral and 0 negative headlines.
- ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQtimothysykes.com, Sep 26
- Is ImmunityBio (IBRX) A Bargain As Turkey Expansion Fuels Fresh Growth Hopes?Simply Wall Street, Sep 25
- ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 24
- State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRXDefense World, Sep 24
- ImmunityBio Advances Patient-Centric Clinical Trial Design in Bladder CancerOncodaily, Sep 23
- ImmunityBio, Inc. Tokenized Stock (Robinhood) to Euro Price Today | Live IBRX to EUR Converter & Exchange RateCryptoRank, Sep 23
ImmunityBio peers
ImmunityBio’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
ImmunityBio stock FAQ
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $8.92B at the Sep 28, 2026 close of $8.52, with 1.06B shares outstanding.
What is the ImmunityBio stock forecast?
The consensus analyst 12-month price target for ImmunityBio is $12.75, +49.6% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ImmunityBio stock overvalued or undervalued?
On Gekko’s estimate ImmunityBio is undervalued: the Sep 28, 2026 close of $8.52 is 13.1% below Gekko Fair Value of $9.81. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ImmunityBio report earnings next?
ImmunityBio is expected to report on Nov 3, 2026 (35 days away). Analysts expect earnings of −$0.08 per share on revenue of $59.23M. ImmunityBio beat the earnings estimate in 5 of its last 8 reports, moving 10.4% on average across the report.
What is ImmunityBio’s 52-week high and low?
ImmunityBio’s 52-week high is $12.43 and its 52-week low is $1.95; it closed at $8.52 on Sep 28, 2026, +246.3% over the past year.
Is ImmunityBio stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 2 as mixed (gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ImmunityBio the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.